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GENE THERAPY
B cell–specific lentiviral gene therapy leads to sustained B-cell functional
recovery in a murine model of X-linked agammaglobulinemia
Hannah M. Kerns,1 Byoung Y. Ryu,1 Brigid V. Stirling,1 Blythe D. Sather,1 Alexander Astrakhan,2 Stephanie Humblet-Baron,3
Denny Liggitt,4 and David J. Rawlings1,2,5
1Center for Immunity and Immunotherapies, Seattle Children’s Research Institute, WA; 2Department of Immunology, University of Washington School of
Medicine, Seattle; 3Center for Cellular and Molecular Therapy, GIGA-R, University of Lie`ge, Lie`ge, Belgium; and Departments of 4Comparative Medicine and
5Pediatrics, University of Washington School of Medicine, Seattle
The immunodeficiency disorder, X-linked
agammaglobulinemia (XLA), results
from mutations in the gene encoding
Bruton tyrosine kinase (Btk). Btk is re-
quired for pre-B cell clonal expansion
and B-cell antigen receptor signaling.
XLA patients lack mature B cells and
immunoglobulin and experience recur-
rent bacterial infections only partially
mitigated by life-long antibody replace-
ment therapy. In pursuit of definitive
therapy for XLA, we tested ex vivo gene
therapy using a lentiviral vector (LV)
containing the immunoglobulin en-
hancer (E) and Ig (B29) minimal pro-
moter to drive B lineage–specific hu-
man Btk expression in Btk/Tec/ mice,
a strain that reproduces the features of
human XLA. After transplantation of
EB29-Btk-LV–transduced stem cells,
treated mice showed significant, albeit
incomplete, rescue of mature B cells in
the bone marrow, peripheral blood,
spleen, and peritoneal cavity, and im-
proved responses to T-independent and
T-dependent antigens. LV-treated B cells
exhibited enhanced B-cell antigen recep-
tor signaling and an in vivo selective
advantage in the peripheral versus cen-
tral B-cell compartment. Secondary
transplantation showed sustained Btk
expression, viral integration, and partial
functional responses, consistent with
long-term stem cell marking; and serial
transplantation revealed no evidence
for cellular or systemic toxicity. These
findings strongly support pursuit of B
lineage–targeted LV gene therapy in hu-
man XLA. (Blood. 2010;115:2146-2155)
Introduction
The primary humoral immunodeficiency, X-linked agammaglobu-
linemia (XLA), is characterized by a block in early B-cell
development leading to a severe reduction in generation, activa-
tion, and survival of mature B-lineage cells.1,2 Antibody responses
and circulating immunoglobulin levels are profoundly decreased,
and affected males develop life-threatening bacterial infections.
Current therapy consists of chronic administration of intravenous
immunoglobulin and antibiotics. This is only partially effective,
expensive, and associated with several long-term complications.
The related immunodeficiencies, XLA and murine X-linked
immunodeficiency (XID), result from deficient function of the
nonreceptor tyrosine kinase, Bruton tyrosine kinase (Btk). Btk is
expressed at all stages of B-lineage development, from pro-B to
mature B cells, and is down-regulated in plasma B cells.3 Btk is
also expressed in erythroid precursors, myeloid cells, mast cells,
and megakaryocytes, but absent in T and NK lineages. Btk is
required for pre–B-cell expansion and mature B-cell survival and
activation via signals initiated by pre–B-cell antigen receptors
(pre-BCRs) and B-cell antigen receptors (BCRs), respectively.
There is a strong selective advantage for B-lineage cells
expressing a normal Btk gene. XLA carrier females and female
Btk/ mice exhibit nonrandom X-inactivation in both bone
marrow (BM) and peripheral B-lineage populations.4,5 Transplanta-
tion of normal BM or fetal liver cells can rescue immune responses
in XID mice without marrow conditioning.6,7 Serum immunoglobu-
lin levels and T-independent type 2 (TI-II) immune responses can
be restored in sublethally irradiated animals with as few as
2.5  104 donor cells and reconstitution of less than 10% WT cells
in the spleen.8 These observations have suggested that introduction
of the normal BTK cDNA into autologous hematopoietic stem cells
(HSCs) might lead to immunologic reconstitution, an improved
quality of life, and increased life expectancy in XLA. In support of
this idea, we previously demonstrated rescue of Btk-dependent
B-cell development and function in Btk-deficient mice using a
recombinant gammaretroviral vector (RV) expressing human Btk.9
Notably, recent work has shown that RV-based HSC gene
therapy can provide significant clinical benefits in patients with
severe combined immune deficiency (SCID).10,11 Unfortunately,
RV therapy in both X-linked SCID and chronic granulomatous
disease has led to unanticipated adverse events because of LTR-
mediated, proto-oncogene transcriptional activation.12,13 Thus, acti-
vating RV insertions can lead to emergence of clonal dominance, as
well as clonal fluctuation, which may also eliminate or reduce
ongoing clinical benefit.
These events have focused attention on self-inactivating (SIN)
lentiviral vectors (LVs) as potential alternative delivery platforms
for hematopoietic disorders. LVs offer the advantage of targeting
nondividing cells and can efficiently target multipotent, nonhuman
primate or human HSCs at low viral copy number.14,15 LVs also
limit the risk of viral LTR enhancer mutagenesis and permit the use
of lineage-specific expression cassettes.16 Further, there is less
evidence for transcriptional silencing of internal promoters within
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integrated LV and no bias for integration within transcription start
sites.17,18 These combined features probably reduce the overall risk
of LV-mediated mutagenesis.
Following up on our initial success with RV Btk gene therapy,
we developed a novel LV optimized for expression in B cells.
Transplantation of transduced, lineage-negative (lin), HSCs into
myeloablated Btk/Tec double-knockout (Btk/Tec/) recipients led
to progressive rescue of central and peripheral Btk-dependent,
B-lineage development, and improved TI-II immune responses and
proliferation in response to B-cell mitogens. Mature B cells derived
from Btk-transduced stem cells exhibited a progressive selective
advantage, and BM derived from primary recipients also partially
rescued B-cell development and function in secondary transplanted
hosts, without evidence for acute or long-term toxicity.
Methods
More detailed methodology is provided in supplemental data (available on
the Blood website; see the Supplemental Materials link at the top of the
online article).
LV constructs and viral production
The EB29 promoter/enhancer was generated by combining the murine
immunoglobulin heavy chain enhancer with 5 and 3 MAR elements19,20
(E) in association with a minimal promoter element derived from the B29
gene (184-bp of the murine promoter, including 166 to 18 from the
major transcriptional start site).21 The LV, pRRL-EB29-Btk, was gener-
ated by replacing phosphoglycerate kinase–green fluorescent protein (PGK-
GFP) sequences from pRRL-SIN-cppt-PGK-GFP-WPRE22 with EB29,
and a full-length human BTK cDNA. pRRL-EB29-Btk-2A-GFP was
generated by insertion of a self-cleaving 2A-GFP sequence in frame with
BTK cDNA. LVs were produced by transient transfection of 293T cells
using standard CaPO4 methods and concentrated by low-speed centrifuga-
tion. Viral titers were determined by real-time quantitative polymerase
chain reaction (PCR).
Stem cell transduction and transplantation
Control C57BL/6 mice (The Jackson Laboratory) and Btk/Tec/ mice23
were maintained in the specific pathogen–free barrier facilities at Seattle
Children’s Research Institute. Animal studies were carried out with the
approval of Seattle Children’s Research Institute Institutional Animal Care
and Use Committee. BM harvested from 6- to 16-week-old mice was
subject to magnetic bead lineage depletion (StemCell Technologies), and
isolated Lin BM cells were transduced overnight in media (StemSpan
SFEM; StemCell Technologies) containing mSCF and mTPO (10 g/mL;
PeproTech), with or without concentrated EB29-Btk-LV at indicated
multiplicity of infection (MOI). After transduction, lethally irradiated
(900-1100 cGy) Btk/Tec/ mice were transplanted with approximately
1  106 Lin BM cells. For secondary transplantation, total BM (5-
10  106) derived from primary recipients was injected into cohorts (2 or
3 secondary recipients/donor) of lethally irradiated Btk/Tec/ mice.
Transplanted mice were evaluated by serial peripheral blood analyses
beginning at 5 weeks, immunization with T-independent (TNP-Ficoll) or
T-dependent (NP-CGG) antigens beginning at approximately 15 weeks,
and cohorts were killed at 24 to 26 weeks for complete developmental and
functional analysis.
Flow cytometry
Single-cell suspensions prepared from BM, spleen, PB, and peritoneal
washes were incubated with fluorochrome-conjugated antibodies for 30 min-
utes at 4°C (see supplemental data for list of antibodies used). Cytofix/
Cytoperm and Alexa 647–conjugated anti–human Btk (53/BTK) were used
for intracellular Btk staining (BD Biosciences PharMingen). Cell analysis
was performed using FACSCalibur and LSRII flow cytometers (BD
Biosciences) and FlowJo software (TreeStar). Total cell numbers were
determined for BM, spleen, and peritoneal cavity by multiplying subset
percentages (expressed as percentage of live cells) by total tissue cell
counts.
Immunizations
For T cell–independent immunization, mice were injected intraperitoneally
with 10 g of TNP-Ficoll (Biosearch Technologies) and sera collected at
days 10 to 14 after immunization. Total IgM, total IgG3, TNP-IgM, and
TNP-IgG3 were evaluated using enzyme-linked immunosorbent assays
(ELISAs), as described previously.9 For T cell–dependent immunization, a
subset of mice that did not see TNP-Ficoll were injected intraperitoneally
with 100 g of NP-CGG in 100 L of alum and sera collected at days 0, 7,
and 14 after immunization. NP-IgM was evaluated at days 0 and 7, and
NP-IgG was evaluated at days 0 and 14.
Viral copy number determination
Quantification of viral integration was adapted from a previously described
protocol.9 Briefly, genomic DNA (gDNA) was obtained from total BM,
spleen, or magnetically separated CD43 and CD43 splenocytes (Miltenyi
Biotec). Gag-specific primer/probe sets (see supplemental data for se-
quences) were used to amplify viral integrations, and a murine -actin
primer/probe set was used to normalize DNA content. Viral integration
number was determined via a standard curve established using gDNA
extracted from A20 murine B-cell line containing a single LV integration.
Calcium flux, cell proliferation, and colony-forming unit cell
assays
Calcium flux measurements were performed as previously described24 after
loading of cell lines or splenocytes with AM Ester Indo-1 (Invitrogen).
Splenocytes from treated mice were cultured with mitogens, loaded with
3H-thymidine, and analyzed for proliferation; splenocytes or BM colony-
forming units were determined as previously described.9
Immunohistochemistry
Frozen sections (6 m) were obtained from mouse spleens embedded in
OCT medium (Sakura). After fixation and blocking, slides were stained at
room temperature for 30 minutes with biotin-conjugated anti–MOMA-1
(BMA Biomedicals), Alexa 647–conjugated anti-IgM (Invitrogen), and
fluorescein isothiocyanate–conjugated anti-IgD (BD Biosciences); and then
stained with Alexa 568–conjugated streptavidin (Invitrogen) and photo-
graphed with identical settings for all images using a Leica DM6000B
microscope with an HCX PL Fluotar 10/0.30 NA objective (original
magnification, 100), a Leica DFC360FX monochrome camera, and LAS
AF6000E software (Leica Microsystems). No imaging medium was used.
Brightness and contrast were adjusted identically using Adobe Photoshop
Version 10.
Statistical analysis
Statistical analyses of relative Btk marking and viral copy numbers were
carried out using a 2-tailed paired Student t test comparing the indicated
experimental cell populations. All other statistical measurements were
carried out using a 2-tailed unpaired Student t test to compare data from LV
versus mock-treated Btk/Tec/ recipients.
Results
Design and in vitro testing of a novel B lineage–specific Btk-LV
To avoid the potential risks associated with ubiquitous LTR
promoter-driven Btk expression, we initiated studies using a novel
SIN LV containing a B lineage–specific internal promoter/
enhancer. We used an LV vector, RRL-EB29-Btk (EB29-Btk;
Figure 1A), containing a minimal promoter derived from the B29
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gene (also known as Ig, CD79b) in conjunction with the
immunoglobulin heavy chain intronic enhancer, E, to drive
expression of a human BTK cDNA. B29 is a key signaling
component of the BCR, expressed in a pattern nearly identical to
Btk. Extensive analyses using a related LV containing only a GFP
marker gene demonstrated that the EB29 promoter/enhancer
mediates high-level, B lineage–restricted expression in murine and
human, BM- and splenic-derived, primary B-cell subsets (B.D.S.
and D.J.R., manuscript submitted).
The capacity of EB29-Btk to restore Btk function was initially
tested in an avian B lymphoma cell line, Btk/ DT-40.25 Cells
were transduced with EB29-Btk-2A-GFP (Figure 1B) at low MOI
to bias for populations with low viral copy number (GFP marking
 10%; Figure 1B left panel), and Btk marking was confirmed by
intracellular flow cytometry (Figure 1B middle panel). Btk func-
tions as a highly specific phospholipase C kinase and a scaffold,
concurrently regulating phospholipase C2 activity by site-specific
phosphorylation and by facilitating its access to its enzymatic
substrate.26 Through these activities, Btk controls the sustained
calcium signal triggered in response to either pre-BCR or BCR
engagement. As shown in Figure 1B (right panel), the Btk
expressing (GFP) subset exhibited rescue of BCR-triggered,
Btk-dependent calcium signal, whereas the Btknull/GFP popula-
tion failed to respond. In contrast, both populations responded to
control ionomycin stimulation (data not shown).
Next, we generated a series of EB29-Btk–transduced, Btk/
DT-40 B-cell clones by limiting dilution to assess functional
recovery in single viral integrant clones (demonstrated by Southern
blotting; not shown). Btk expression was confirmed using FACS
and Western blotting, and rescue of the Btk-dependent calcium
signal was observed in multiple independent B-cell clones (supple-
mental Figure 1). In addition, EB29-Btk rescued the calcium
signal in LV-transduced, sIgM LMP2 EBV B-cell lines derived
from XLA patients27 (data not shown), showing functional activity
in Btk-deficient mammalian as well as in avian B cells.
EB29-Btk restores BM and peripheral B-cell development in
Btk/Tec/ mice
Based on these findings, we initiated studies of EB29-Btk gene
therapy using Btk/Tec/ mice, a strain that accurately mimics the
B-cell developmental and functional phenotype of human XLA.23
Lin BM cells were transduced (MOI 3-100) and transplanted into
lethally irradiated recipients. As positive and negative controls,
respectively, additional cohorts of Btk/Tec/ recipients were
transplanted with Lin BM derived from either C57/Bl6 wild-type
(WT mock) or Btk/Tec/ (KO mock) mice, cultured under
identical conditions in the absence of LV.
Btk/Tec/ mice exhibit decreased total and mature B-cell
numbers in the BM, PB, spleen, and peritoneal cavity. As shown in
Figure 2A, within 16 to 19 weeks after transplantation, analysis of
PB revealed a marked increase in both total and Hardy fraction I
(IgMloIgDhi) mature B cells in recipients of EB29-Btk–trans-
duced, Lin HSCs: MOI 15 to 25 (30.7% 	 13.8% total B and
20.9% 	 5.3% fraction I, respectively) and MOI 50 to 100
(26.8% 	 8.3% and 23.4% 	 6.0%), compared with KO mock
(11.5% 	 5.7% and 5.6% 	 1.3%). Only a modest increase in PB
B-cell numbers was observed using MOI 3 (20.1% 	 10.1% and
12.6% 	 9.2%). LV MOI 3 was insufficient to significantly reverse
these cellular deficits. In contrast, MOI 15 to 100 consistently
restored B-cell numbers, and similar rescue was observed using
“medium” (15-25) versus “high” (50-100) MOI (4 independent
experiments).
To evaluate the capacity to reconstitute the B-cell lineage in
greater detail, recipient animals were killed at 24 to 26 weeks
after transplantation. Cells were isolated from BM, spleen, and
peritoneal cavity, and absolute numbers and the relative percent-
age of each B-cell subset were assessed using flow cytometry
(Figure 2B-D and supplemental Figure 2A-C, respectively).
Within the BM, LV- and mock-treated controls exhibited similar
numbers of pro/pre-B cells (Figure 2B). In contrast, mice at
MOI 15 to 25 and MOI 50 to 100 showed significant increases in
the percentage and number of immature and recirculating
B cells compared with KO mock controls. Interestingly, LV-
treated mice had larger numbers of immature B cells compared
with WT controls, perhaps because of reduced competition for
niche space with mature recirculating B cells, present in some-
what lower numbers in LV-treated mice.
In the spleen, EB29-Btk–treated mice exhibited a signifi-
cant increase in total B cells. This reflected an increase in each
of the major splenic B-cell subsets, including transitional
(T1/T2), marginal zone (MZ)/MZ progenitors, and follicular
mature (FM; Figure 2C); and of progressively more mature
Hardy fraction II (Fr II) and I (Fr I) B cells (Figure 2D).
Although significantly increased, the absolute number of FM
B cells remained below that in WT mock recipients, and
LV-treated animals also exhibited greater variability in FM cell
numbers. Thus, LV gene transfer rescued the key mature
populations, FM and MZ B cells, required for adaptive and
innate B-cell immune responses, respectively.
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Figure 1. EB29-Btk-LV restores calcium flux in
Btk-deficient B cells. (A) Schematic of the LV EB29-
Btk used for all murine transplantation experiments.
Expression of the human BTK cDNA transgene is driven
by a B29 (Ig) minimal promoter in conjunction with an Ig
heavy chain enhancer (E). (B) Schematic of EB29-Btk-
2A-GFP (Btk-GFP) vector used in DT40 transduction
experiments. Btk-deficient DT40 chicken B cells were
transduced at limiting MOI and evaluated for GFP and
Btk expression by FACS (left panels). Transduced cells
were stimulated with anti-IgM and analyzed for calcium
flux within the GFP vs GFP fractions (right panel).
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Btk/Tec/ mice fail to generate peritoneal B1 B cells,
essential for rapid, innate-like responses to serosal or blood-
borne infection with encapsulated bacteria.28 Within the B1
population, CD5 B1a cells compose a specialized, more mature
(probably antigen experienced) population distinct from CD5
B1b cells. EB29-Btk–treated mice exhibited a significant
increase in both B1 subsets, with the greatest increase in B1a
B cells at MOI 15 to 25 and 50 to 100.
Btk/Tec/ mice also show structural abnormalities within the
lymphocyte compartments of the spleen, with few or no discern-
able splenic follicles, a disrupted marginal zone, and poor B- and
T-cell segregation.23 To evaluate these parameters, we performed
immunohistochemistry on spleen sections from secondary transplan-
tation mice (Figure 3). Compared with WT controls, WT mock
animals exhibited somewhat less well-developed follicles, presum-
ably because of the impact of lethal irradiation. Spleens from KO
mock recipients (or unmanipulated KO controls; not shown)
exhibited relatively small clusters of IgM B cells, with partially
disrupted follicular structures lacking a distinct MOMA marginal
zone (Figure 3A-D). In contrast, spleens from mice receiving MOI
15 to 25 BM exhibited follicles similar in number and size to WT
mock controls, containing both IgM and IgD B cells and a
well-demarcated MOMA border ringed by IgM MZ B cells
(Figure 3E-F).
EB29-Btk–expressing B cells demonstrate a strong selective
advantage
Over the course of each EB29-Btk gene transfer experiment, we
observed a progressive increase in the relative percentage of Btk
PB B cells. In the representative experiment shown (Figure 4A),
Btk B cells increased approximately 2- to 3-fold between weeks
5 and 24 at MOI 3 and MOI 15 to 25; and these Btk cells exhibited
a mean fluorescent intensity equivalent to WT B cells. In contrast,
although a small percentage of Btk myeloid cells were consis-
tently observed in LV-treated mice (reflecting partial myeloid
lineage promoter/enhancer activity; data not shown), this marking
level did not increase over time. Consistent with lack of selection
Figure 2. EB29-Btk gene therapy restores central and peripheral B-cell development. PB, BM, spleen, and peritoneal cells from LV-treated mice and mock controls were
stained for surface markers and analyzed by flow cytometry to identify B-cell subsets (supplemental Figure 2, gating strategy). (A) PB cells were first gated on live and CD11b
populations and then analyzed for B220, IgM, and IgD expression. FACS plots show representative mice from WT mock (n 
 7), KO mock (n 
 8), MOI 3 (n 
 3), and MOI
15 to 25 (n 
 12) experimental groups. (B-E) Total cell numbers in each B-cell subset were determined for BM, spleen, and peritoneal cavity. In bar graphs, KO data include
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and/or promoter activity, Btk T cells were undetectable at all time
points.
The progressive increase in PB B-cell marking reflects the
strong selective pressure for Btk B cells in Btk/Tec/ mice. This
selective advantage was evident both in the BM and in peripheral
lymphoid compartments in treated animals. For example, in mice
treated with MOI 15 to 25, the relative percentage of Btk BM
B cells increased during the pro/pre to immature B-cell transition
(Figure 4B). Increased marking was also evident as immature
B cells entered the periphery and matured into splenic transitional
(T1/T2) and FM B cells, and was most striking in peritoneal B1
B cells. Selection for Btk B cells correlated with increased
relative cell numbers at each of these sequential developmental
checkpoints.
Consistent with these data, we observed an increase in the
average number of viral integrations per cell in spleen relative to
BM derived cells. This difference was most prominent at MOI
50 to 100, where total BM cells had an average of 1.9 plus or minus
0.7 copies compared with 2.5 plus or minus 0.7 copies in splenic
B cells (Figure 4C). A significant copy number difference was also
observed in splenic B versus non–B-cell populations at all MOIs.
Viral copy number was also generally higher in total BM cells
compared with splenic non-B cells, most probably because of the
presence of recirculating mature B cells within the BM population.
Combined with the analysis of Btk protein expression, these data
demonstrate a strong selective advantage for EB29-Btk B cells
in Btk/Tec/ mice, highlighting that even relatively low initial
marking levels can lead to large numbers of gene-marked Btk
cells in the periphery. Of note, consistent with multilineage
transduction, sustained viral marking was identified in B cell–
depleted BM cells isolated from all LV-treated mice at the time of
death (average, 1.4 	 0.4 copies for MOI 15-25 at weeks 24-26;
data not shown).
EB29-Btk restores Btk-dependent B-cell functional responses
Btk/Tec/ B cells fail to generate a sustained calcium signal in
response to BCR ligation. Thus, calcium signaling was assessed in
splenocytes derived from one experimental cohort using anti-IgM
versus ionomycin (control) stimulation. Mice treated with MOI 15
to 25 exhibited an improved anti-IgM calcium flux compared with
KO mock controls (Figure 5A). The partial (compared with WT
mock control), population-based, calcium response in EB29-Btk–
treated mice mirrored the relative Btk expression in splenic B cells















































































































































Figure 4. Btk B cells exhibit progressive selective advantage. (A-B) PB, BM, spleen, and peritoneal cells were stained for surface markers and intracellular Btk and
analyzed by flow cytometry. (A) Representative data showing Btk expression in PB B cells analyzed at weeks 5, 17, and 24 after transplantation. FACS plots show
representative mice from WT mock (n 
 7), KO mock (n 
 8), MOI 3 (n 
 3), and MOI 15 to 25 (n 
 12) experimental groups. (B) Btk cells in various B-cell subsets displayed
according to increasing maturity in BM and periphery in MOI 15 to 25 LV-treated mice. (C) gDNA derived from total BM, splenic non-B (CD43), and B (CD43) cell populations
was evaluated for viral copy number. Data represent 4 independent experiments. ***P  .001; **P 










Figure 3. EB29-Btk-LV therapy restores splenic follicular morphology. Frozen
sections from secondary transplantation mice were stained for IgM (blue), IgD
(green), and MOMA (red) and then imaged using fluorescence microscopy. Slides
were analyzed for the presence of follicles, indicated by IgMloIgDhi follicular B cells
(green) separated from IgMhiIgDlo marginal zone B cells (blue) by a ring of MOMA
marginal zone macrophages (red). Images show representative spleen sections from
a WT control mouse (A) and recipients of WT mock (B), KO mock (C-D), and LV MOI
15- to 25-treated BM (E-F).
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WT and KO mock cells responded similarly to ionomycin
stimulation.
Btk/Tec/ mice manifest defects in B-cell proliferation in
response to either BCR engagement or stimulation with TLR4
ligands (eg, lipopolysaccharide [LPS]). Splenocytes were cultured
in media containing anti-IgM, LPS, or phorbol myristate acetate
(PMA)-ionomycin and assayed for proliferation using 3H-
thymidine incorporation (Figure 5B). Increased proliferation in
response to IgM or LPS was observed in all LV-treated animals
compared with KO mock recipients. At 20 g/mL IgM, MOI 3
showed increased proliferation compared with KO control
(12 099 	 13 872 vs 1354 	 1193, respectively). MOI 15 to 25
and MOI 50 to 100 showed much greater increases in proliferation
(40 185 	 27 290 and 31 074 	 18 779 cpm, respectively), and
enhanced responses were also observed using lower-dose anti-IgM
or LPS. All populations exhibited similar responses to PMA/
ionomycin, a combined stimulus that bypasses the requirement for
Btk in proximal BCR signaling.
To test the ability to proliferate to antigen in association with
TLR signals, we cultured BM or spleen cells with sheep red blood
cells and LPS in an agar-based, colony-forming assay (Figure 5C).
Btk/Tec/ cells failed to respond to these signals (BM, 0.0 	 0.1
colonies; spleen, 0.1 	 0.3 colonies). In contrast, colony formation
was observed with both BM (MOI 3, 1.3 	 1.3 colonies; MOI
15-25, 4.5 	 3.0 colonies; MOI 50-100, 4.8 	 4.0 colonies) and
splenocytes (MOI 3, 16.2 	 7.3 colonies; MOI 15-25, 39.7 	 12.5
colonies; MOI 50-100, 34.8 	 23.8 colonies) derived from LV-
treated mice. The lower colony numbers using BM probably reflect
the smaller relative proportion of mature B cells compared with the
spleen. Similar to the calcium signal, the partial response of splenic
B cells (compared with WT control) in both the colony-forming
and 3H-thymidine assays correlated with the relative levels of Btk
expression in individual EB29-Btk–treated mice.
Striking features characteristic of both XLA patients and
Btk/Tec/ mice are very low levels of serum immunoglobulin and
the inability to mount T-independent antigen responses. Serum
levels of IgM in nearly all EB29-Btk–treated mice were markedly
increased compared with KO controls (KO, 14.0 	 5.7 relative
units; MOI 3, 132.3	 38.3 relative units; MOI 15-25, 120.1	 88.2
relative units; MOI 50-100, 115.0 	 81.9 relative units; Figure
6A). A similar, but smaller, increase was seen for serum IgG3. After
immunization with the TI-II immunogen, TNP-Ficoll, the majority
of LV-treated mice produced significant levels of TNP-specific IgM
(KO, 3.5 	 2.0 relative units; MOI 3, 20.4 	 8.8 relative units;
MOI 15-25, 12.7 	 8.0 relative units; MOI 50-100, 7.7 	 6.7
relative units). Similarly, most treated animals also generated
significant IgG3 anti-TNP responses (data not shown).
We also tested T-dependent antigen responses using immuniza-
tion with NP-CGG in alum in a small cohort of mice that were not
immunized with TI-II immunogen. LV-treated mice (MOI 10)
showed a 6.9-fold increase in NP-specific IgM between day 0 and
day 7 compared with 11.8-fold and 3.2-fold increase in WT and
Btk/Tec/ mice, respectively (Figure 6B). In addition, LV-treated
animals exhibited a 104-fold increase in NP-specific IgG at day 14,
Figure 5. EB29-Btk gene therapy restores Btk-dependent BCR and mitogen signaling. BM and splenocytes cells were assessed using various functional assays at the
time of harvest. (A) In 1 of 4 experiments, splenocytes were stained for surface markers, stimulated with anti-IgM or ionomycin, and analyzed for calcium flux. Representative
traces from B220 cells in WT mock (n 
 1), KO mock (n 
 1), and MOI 15 to 25 (n 
 4) experimental groups are shown. (B) Splenocytes were analyzed for cell proliferation in
response to anti-IgM, LPS, or PMA/ionomycin stimulation. (C) BM or splenocytes cells were analyzed for colony-forming unit cell production. WT and KO datasets include both
unmanipulated and mock-transplanted animals. Data represent 4 independent experiments, unless otherwise noted. P values compare EB29-Btk vs KO groups: ***P  .001;
**P 
 .001-.01; *P 
 .01-.05.
Figure 6. Improved T-independent and T-dependent immune responses in
EB29-Btk-LV–treated mice. Mice were immunized with TNP-Ficoll or NP-CGG in
alum at 15 to 17 weeks after transplantation. (A) Sera levels of IgM, IgG3, and
TNP-IgM at day 14 after immunization were analyzed by ELISA and expressed
relative to IgM or IgG3 standard curves. (B) Sera levels of NP-IgM were evaluated by
ELISA at days 0 and 7, and levels of NP-IgG were evaluated at days 0 and 14. WT
and KO datasets include both unmanipulated and mock-transplanted animals. Data
represent 4 independent experiments (A) and 1 experiment (B). P values compare
EB29-Btk and KO groups: ***P  .001; **P 
 .001-.01; *P 
 .01-.05.
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compared with a 342-fold increase for WT and a 41-fold increase
for KO animals. Although the numbers of mice tested thus far are
still too few to yield statistical significance, these data demonstrate
a clear trend toward improved T cell–dependent immune responses
in LV-treated mice.
Together, these data demonstrate that EB29-Btk gene therapy
is capable of improving critical B-cell functional responses absent
in Btk/Tec/ mice, including proximal and downstream responses
to BCR engagement and antibody responses.
Sustained LV-driven Btk expression and activity after
secondary transplantation
We also used secondary bone marrow transplantation to assess the
long-term efficacy and potential toxicity of EB29-Btk gene
therapy. Cohorts of secondary transplantation recipients were
established from each primary experimental group. At 19 to
21 weeks after secondary transplantation, recipients of MOI 15 to
25 treated primary BM had significantly higher percentages of
mature Fr I PB B cells compared with KO mock controls
(24.6% 	 14.4% vs 6.2% 	 5.7%; Figure 7A), with an average
Btk marking similar to that in the primary donor pool (Figure 7B,
compare shaded area with dark bars); however, secondary recipi-
ents manifest greater variability. For example, several mice exhib-
ited levels of Fr I and Btk cells nearly identical to WT controls,
reflecting ongoing positive selection for Btk B cells. In contrast,
other secondary recipients had much lower levels of Btk cells,
suggestive of LV silencing after HSC expansion in response to
serial engraftment.
Similar to primary recipients, we identified an increase in
relative viral copy number in spleen versus BM, and splenic B
versus non-B cells in secondary recipients (MOI 15-25, BM,
1.5 	 0.7 copies; splenic B, 3.3 	 0.7 vs non-B, 1.8 	 0.4 copies;
Figure 7C). Compared with their respective donors, most recipients
exhibited similar BM copy number and slightly greater average
copy number in splenic B cells, consistent with an ongoing
selective advantage for marked B cells. Interestingly, secondary
recipients with lower percentages of Btk Fr I B cells (7.2%, 4.2%,
and 17.8%) exhibited splenic B-cell marking (1.5, 0.5, and 2.58
copies, respectively) indistinguishable from animals with high-
level Btk expression, providing additional evidence for silencing or
variegation of LV expression in this subset of animals.
Finally, we assessed functional responses in cohorts of second-
ary recipient mice. Splenocytes were cultured with anti-IgM, LPS,
or PMA/ionomycin to measure proliferative capacity. Secondary
recipients (MOI 15-25; and MOI 50-100, not shown) demonstrated
strong proliferative responses to anti-IgM and LPS (Figure 7D). In
addition, mice were immunized with TNP-Ficoll beginning at
17 weeks after transplantation. MOI 15 to 25 and MOI 50 to 100
LV-treated recipients exhibited partial recovery of serum IgM and
TNP-specific IgM (Figure 7E; and data not shown). Recipients of
MOI 3-treated BM exhibited limited and highly variable functional
responses. These data indicate that EB29-Btk gene therapy leads
to sustained stem cell marking and partial rescue of Btk-dependent
developmental and functional responses in the majority of second-
ary transplanted mice.
Lack of evidence for toxicity in EB29-Btk–treated mice
We performed an extensive histologic analysis to monitor for
potential tissue pathology in 38 EB29-Btk–treated or control
mice. Nonirradiated WT and KO control animals did not show
abnormal features in any examined tissues. In contrast, all animals
receiving total body irradiation, including WT and KO mock-
treated animals, exhibited moderate to severe lung fibrosis, hemor-
rhage, and inflammation, as well as limited renal glomerular injury
(supplemental Table 1). Instances of focal degeneration of the liver
and pancreas were also recorded in both mock and EB29-Btk
animals. In addition, analysis of secondary recipients with the
highest viral copy numbers did not identify abnormal results
compared with mock recipients. Complete blood counts (CBCs)
were also performed on 53 secondary transplantation recipients at
approximately 24 weeks after transplantation and for 12 unmanipu-
lated controls. We observed no significant differences in platelet,
Figure 7. Secondary transplantation reveals sustained marking of Btk/Tec/ hematopoietic stem cells and partial correction of functional deficits. PB, BM, and
spleen cells were harvested from secondary recipients at weeks 19 to 27 after transplantation. Cells were subjected to flow cytometric analysis, quantitative PCR copy number
determination, and functional assays, as described for primary transplantation experiments. (A) PB cells were analyzed for the percentage of IgMloIgDhi (Fr I) mature B cells
and compared with primary transplantation donors (shaded bars). (B) PB cells were analyzed for Btk Fr I B cells and compared with donor percentages (shaded bars).
(C) gDNA from total BM, splenic non-B (CD43), and B (CD43) cell populations was evaluated for viral copy number and compared with donors (shaded bars).
(D) Splenocytes were analyzed for cell proliferation in response to anti-IgM, LPS, or PMA/ionomycin stimulation. (E) IgM and TNP-specific IgM were analyzed in immunized
mice by ELISA and expressed relative to IgM standard curves. WT and KO datasets include both unmanipulated and mock-transplanted animals, unless otherwise noted. Data
represent 3 independent experiments. P values compare EB29-Btk and KO groups or indicated B-cell subsets: ***P  .001; **P 
 .001-.01; *P 
 .01-.05.
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monocyte, neutrophil, or T-cell counts in gene-treated versus
control animals (supplemental Table 2).
Finally, we evaluated a subset of transplanted mice for viral
integration pattern using linear amplification mediated (LAM)–
PCR. Analysis was performed for primary and secondary recipi-
ents, including animals that exhibited the highest levels of Btk
marking (supplemental Figure 3). All recipients exhibited evidence
for polyclonal marking in splenocytes and purified B cells. One
common insertion site was found both in purified B cells and
non-B cells derived from the spleen of a primary animal. In
addition, another common insertion site was present in both
non-B cells from the primary animal and purified B cells of a
secondary recipient; both common insertions are consistent with
long-term stem cell marking (data not shown). Importantly, al-
though a subset of secondary recipients exhibited an increase in
relative Btk marking (and, to a lesser extent, in viral copy number)
compared with primary donors, we observed no evidence for clonal
dominance in this setting. Consistent with these findings, we have
not observed evidence for integration-related leukemic outgrowth
in EB29-Btk–treated animals (including 29 primary, 44 second-
ary, and 20 tertiary recipients followed for at least 20 weeks).
Discussion
Despite current comprehensive care, studies in genetically defined
XLA patients indicate that infectious and noninfectious morbidity
remains high, with survival rates as low as 50% by age 4529,30 (A.
Plebani, Universita` di Brescia, oral communication at the XIIth
Meeting of the European Society for Immunodeficiencies, October
4-7, 2006). Although prospective studies31-33 indicate that the
overall prognosis in XLA is improved after earlier recognition and
consistent immunoglobulin replacement and antibiotic therapy,
these measures remain incompletely protective. Many patients
experience chronic mucosal-surface infections and others die of
fulminant bacterial infection, neurodegenerative disease, or malig-
nancies. Our studies represent an important first step toward
development of B lineage–targeted LV delivery as an alternative
therapeutic approach in XLA.
Our combined data provide the first demonstration of successful
ex vivo LV gene therapy in an animal model of XLA. Transplanta-
tion of EB29-Btk-LV–transduced Lin BM into lethally irradi-
ated recipients led to a reversal of the severe B-cell developmental
defects in Btk/Tec/ mice. This therapeutic effect was LV
dose–specific, as exposure to LV at MOI 3 led to marking that was
insufficient for disease correction. In contrast, animals treated with
MOI 15 or greater exhibited significant increases in both percent-
age and absolute numbers of mature B-cell subsets in the PB, BM,
and spleen, with rescue of both early and late Btk-dependent
developmental checkpoints. Treated animals also exhibited in-
creased numbers of peritoneal B1 B cells, a critical first line of
defense against infections with encapsulated bacteria. In addition to
recovery of mature B-cell numbers, LV treatment restored proximal
signaling deficits (assessed by calcium flux) and downstream
functional responses, including B-cell proliferative and colony-
forming responses to antigen- and/or Toll-like-receptor engage-
ment, basal IgM and IgG3 production, and T-independent antigen-
specific antibody responses after immunization.
Developmental rescue correlated with a strong selective advan-
tage for virally marked Btk B cells. The overall percentage of
Btk B cells increased throughout the following transplantation
period, and treated mice also exhibited progressive enrichment for
Btk B cells in developmentally maturing B-cell subsets. Selection
for Btk B cells was also further enhanced in a subset of secondary
transplantation recipients. Consistent with the analysis for Btk
protein expression, LV copy number also increased in splenic B
versus non-B cells and splenic B versus BM cells, documenting
selective advantage in the peripheral B-cell compartment. In
contrast, LV marking and Btk expression remained essentially
unchanged in non-B cells.
Our data, showing sustained Btk expression, functional re-
sponses, and viral integration after secondary transplantation, are
consistent with the interpretation that EB29-Btk-LV stably marks
long-term HSCs. Further, an extensive analysis in EB29-Btk–
treated (primary and secondary) transplantation recipients did not
identify any detrimental effects (based on histology and CBCs),
with the exception of changes resulting from the irradiation
conditioning regimen used (present in both LV-treated and control
animals). Extended observation of both primary and secondary/
tertiary recipient cohorts also failed to identify evidence for LV
integration-related toxicity. Consistent with this, LAM-PCR analy-
sis of LV-treated mice revealed a polyclonal integration profile and
no evidence for clonal dominance, even in secondary recipient
animals with the highest level of Btk B cells. Although we did not
identify evidence for systemic autoimmunity based on CBC or
histologic findings, our data cannot rule out the possibility that
differences in BCR-mediated signaling in LV-treated mice might
promote altered B-cell tolerance. Additional studies will be re-
quired to fully address this potential outcome.
These combined observations strongly support the further study
of LV gene therapy for XLA. Compared with other immunodefi-
ciency disorders where gene therapy is being pursued, XLA also
exhibits several unique features. (1) XLA is the most common
primary immunodeficiency exhibiting a selective advantage for
normal or reconstituted lymphoid cells. Because of this and their
longer life expectancy, XLA patients compose a relatively large
cohort for clinical testing. (2) Circulating immunoglobulin has no
effect on the selective advantage of Btk B cells. Thus, in contrast
to disorders, such as adenosine deaminase–deficient SCID, Btk
gene therapy can be pursued without discontinuing definitive
supportive care. (3) Unlike T-cell immune deficiency disorders
where thymic atrophy may limit lymphoid reconstitution in older
persons, B lineage reconstitution (based on autologous transplanta-
tion data) remains efficient across a broad age range. (4) Overex-
pression of WT34 or activated Btk35 does not lead to any observable
risk in animals, and Btk functions as a tumor suppressor, limiting
the risk for pre-B-cell leukemia.36,37 In addition, there is no
evidence that mutant Btk can function in a dominant negative
fashion, implying that all XLA genotypes will be feasible treatment
candidates. (5) The more stable condition of XLA patients (com-
pared with SCID, for example) may permit progressive optimiza-
tion, or perhaps repetitive delivery, of genetic therapies. (6) The
chronic nature of XLA and high cost of long-term administration of
intravenous immunoglobulin (currently estimated at  $75 000/
year) suggest that gene therapy may provide a cost-effective
alternative. (7) Finally, the milder disease phenotype in patients
with partial Btk activity suggests that even limited restoration of
enzymatic activity may provide clinical benefit.38,39
Several observations, however, merit additional attention before
proceeding toward clinical application in XLA:
First, although highly significant, numerical and functional
B-cell reconstitution in EB29-Btk–treated mice was incomplete.
Previous studies using transgenic animals indicate that Btk expres-
sion differentially impacts key developmental versus functional
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outputs, and endogenous levels of Btk are probably required for
full functional correction.40,41 Interestingly, although in vitro prolif-
erative responses in gene-treated mice were less than WT controls,
such responses were essentially normal when adjusted for the
relative percentage of Btk input cells. Increasing the MOI to more
than 25 did not further improve functional recovery, and we
observed evidence suggestive of promoter silencing in some
secondary recipients. Together, these findings suggest that EB29-
Btk-LV is subject to variegation of expression in vivo, as also
evident for other LV,42 and that this may progressively impact
expression in differentiating B cells. Additional work is required to
determine whether incorporation of alternative elements, for ex-
ample, the endogenous Btk promoter43-46 and/or a ubiquitously
acting chromatin opening element,42 may limit such variegation
and enhance functional recovery.
Second, the conditioning regimen used in our studies is
associated with significant toxicity and would not be appropriate
for future clinical trials. Of note, sustained donor B-cell engraft-
ment is not achieved in the majority of B SCID patients (nor in the
small number of XLA patients studied) after BM transplantation in
the absence of conditioning47,48; and host pro-B cells directly limit
B-cell reconstitution in nonconditioned, Rag2/ or MT recipient
mice.49 Btknull pro-B cells are similarly predicted to compete with
gene-corrected donor cells in our XLA model. Therefore, Btk LV
delivery will probably require at least limited marrow cytoreduc-
tion. Thus, it will be essential to determine whether nonmyeloabla-
tive conditioning (with busulfan or a related regimen) will permit
engraftment and Btk marking at levels sufficient for functional
rescue in XLA animal models.
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